MedTrace Logo

Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia

NCT01242371 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2019-02-05

Study results available
· View outcomes & findings →

Summary

The investigators intend to explore the hypothesis that symptoms of schizophrenia may be reduced by the administration of a probiotic supplement when used in addition to standard antipsychotic medications.

Conditions

Interventions

DIETARY_SUPPLEMENT

Probiotic Supplement

Probiotic Supplement 1 tablet by mouth daily

DIETARY_SUPPLEMENT

Identical-appearing Placebo

Probiotic identical placebo 1 tablet by mouth daily

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Sheppard Pratt Health System

    lead OTHER

Principal Investigators

  • Faith B Dickerson, PhD, MPH · Sheppard Pratt Health System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01242371 on ClinicalTrials.gov